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We present the first quantitative analysis of atypical teratoid rhabdoid tumors (ATRT) 
in adults, including two patients from our own institutions. These are of interest as one 
occurred during pregnancy and one is a long-term survivor. Our review of pathological 
findings of 50 reported cases of adult ATRT leads us to propose a solely ectodermal 
origin for the tumor and that epithelial–mesenchymal transition (EMT) is a defining fea-
ture. Thus, the term ATRT may be misleading. Our review of clinical findings shows that 
ATRT tends to originate in mid-line structures adjacent to the CSF, leading to a high rate 
of leptomeningeal dissemination. Thus, we hypothesize that residual undifferentiated 
ectoderm in the circumventricular organs, particularly the pituitary and pineal glands, 
is the most common origin for these tumors. We note that if growth is not arrested 
soon after diagnosis, or after the first relapse/progression, death is almost universal. 
While typically rapidly fatal (as in our first case), long-term remission is possible (as in 
our second). Significant predictors of prognosis were the extent of resection and the 
use of chemotherapy. Glial differentiation (GFAP staining) was strongly associated with 
leptomeningeal metastases (chi-squared p = 0.02) and both predicted markedly worse 
outcomes. Clinical trials including adults are rare. ATRT is primarily a disease of infancy 
and radiotherapy is generally avoided in those aged less than 3 years old. Treatment 
options in adults differ from infants in that cranio-spinal irradiation is a viable adjunct 
to systemic chemotherapy in the adult population. Given the grave prognosis, this 
combined approach appears reasonable. As effective chemotherapy is likely to cause 
myelosuppression, we recommend that stem-cell rescue be available locally.
Keywords: teratoma, rhabdoid tumor, adult, pregnancy, statistical data analysis, statistical data interpretation, 
etiology
Figure 1 | First patient. MRI brain at time of diagnosis, 1.5 T. Images are 
T1-weighted and Gd-enhanced. (a) Axial: heterogeneous extra-axial 
enhancement is seen in the left cerebello-pontine angle, with some local 
compression. (B) Coronal: enhancement is seen along the tentorium cerebelli 
on the right, which is characteristic of leptomeningeal spread. The left 
cerebellar lesion appears intraparenchymal.
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1. inTrODucTiOn
1.1. history of aTrT
ATRT, a cancer of the CNS, was christened by Rorke et  al. in 
1996, following a review of 52 pediatric cases (1). We may trace 
the first appearance of the term “atypical teratoma” to four 
decades earlier, where it was recognized to occur in the pineal 
gland (2). The “atypical” refers descriptively to the “teratoid” part 
of the tumor. This appears to show elements of two germ cell 
layers (ectoderm, i.e., primitive neuroepithelial, epithelial, and 
mesoderm, i.e., “rhabdoid”) but is otherwise quite different from 
classical teratoid tumors. “Rhabdoid” (Greek, “rod-like”) refers to 
the similarity, on microscopy, to tumors showing skeletal muscle 
differentiation.
The biology of and treatment strategies for ATRT (focusing 
on children) have been the subject of a recent, thorough review. 
Although the prognosis in children has traditionally been dismal, 
with few long-term survivors, developments over the last 10 years 
have, at least for children, been encouraging (3). Recently, muta-
tions in the chromatic remodeling complex SMARCB1 (and, as a 
rare alternative, of SMARCA4) have been identified in the great 
majority of cases of ATRT (4). Such mutations appear necessary 
for the development of ATRT; no other consistent genetic abnor-
malities have been identified.
1.2. aTrT in adults
While ATRT is the most common malignant CNS tumor in 
children aged <1, cases in adults (i.e., age >18) are rare—we 
estimate <1/1,000,000 lifetime risk (5). As such, these patients 
are presented in detail as case reports or in small case series. There 
are no molecular markers recognized as unique to adults rather 
than children; in both cases, loss of INI1 staining via immuno-
histochemistry (IHC) is considered sufficient for diagnosis in the 
appropriate context.
1.3. rhabdoid Tumors
ATRT is often described as analogous to “malignant rhabdoid 
tumor of the kidney,” a tumor recognized since at least the early 
1980s (6). Other CNS tumors with rhabdoid histology include the 
“epithelioid glioblastoma with rhabdoid component” as well as 
the “rhabdoid” variants of more common tumors: meningioma, 
carcinoma, chordoma, and even sarcoma (7).
1.4. eMT
Epithelial–mesenchymal transition (EMT) was initially identified 
as a phenomenon in developmental biology. The occurrence of 
EMT in certain cancers has been suggested since 1978, although 
it only began to receive widespread attention 10 years later (8). 
The role of EMT in carcinogenesis has been the subject of an 
extensive review (9). EMT appears to be crucial to the develop-
ment and maintenance of a pool of slowly dividing, chemore-
sistant, “cancer stem cells.” We hypothesize that the “rhabdoid” 
appearance of the tumors above reflects EMT.
2. case rePOrTs
2.1. a case in Pregnancy
2.1.1. Presentation
Our first patient was a 29-year-old woman who developed 
hoarseness during week 20 of her first pregnancy, which deterio-
rated over the subsequent 5 weeks. Over the course of 1 day, she 
developed weakness of the right arm and leg. A CT performed 
elsewhere showed the presence of an extra-axial left cerebello-
pontine mass. This was interpreted as a probable meningioma, so 
further treatment was deferred.
At 35 weeks gestation, she developed status migrainosus and 
worsening right leg weakness. Her voice had become weaker and 
she coughed intermittently when swallowing. Paralysis of her 
left vocal cord was demonstrated via laryngoscopy. Her MRIs at 
this time are shown in Figures 1 and 2. A cesarean section was 
performed in anticipation of neurosurgery and a healthy baby 
boy was delivered.
2.1.2. Initial Treatment
A left retro-sigmoid craniotomy was performed. Pathology, show-
ing loss of immunohistochemical staining for INI1, confirmed 
ATRT. Her spinal MRI showed leptomeningeal metastases in the 
cervical and thoracic cord. She rapidly developed hydrocephalus; 
a shunt and Ommaya reservoir were placed 1 week after surgery.
Multimodal treatment was instituted. Systemic chemotherapy 
involved two cycles (of 14 days) of ICE (ifosfamide, carboplatin, 
etoposide). Following the second cycle, she developed pancyto-
penia and sepsis, and thereafter no further systemic treatment 
was pursued.
Intrathecal chemotherapy was with liposomal cytarabine 
50 mg via Ommaya every 2 weeks; she received 6 doses in total. 
Intensity-modulated radiotherapy to the cerebellum was 54 Gy 
in 30 fractions; conformal radiotherapy to the cord at C5–T6 
Figure 2 | First patient. MRIs of spine, 1.5 T, sagittal. (a) Gd-enhanced: 
diffuse, nodular enhancement is seen throughout. This is striking dorsally and 
at the conus medullaris. (B) T2-weighted: the thoracic cord is swollen with 
intra-medullary edema. This appears to be a reaction to the surrounding 
leptomeningeal tumor; there may also be an element of cord compression in 
the thoracic cord. (c) Gd-enhanced: disease in the upper thoracic cord is 
much improved following radiotherapy. Progression has occurred around the 
untreated cord caudally. (D) T2-weighted: similarly, intra-medullary edema 
has improved in the treated areas but worsened elsewhere.
Figure 3 | Second patient. MRIs of brain. Upper row (a–c): T1-weighted, 
Gd-enhanced (magnetization-prepared rapid gradient-echo (MPRAGE)).  
A suprasellar and interpeduncular lesion is seen with mixed solid and cystic 
(lobulated) elements. There is heterogeneous enhancement of intermediate 
intensity. Lower row (a,B): T1-weighted, Gd-enhanced. There is no 
evidence of tumor recurrence. Smooth linear enhancement is present at the 
resection site, which is consistent with the long-term changes seen 
following surgery.
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vertebral levels was 30 Gy in 10 fractions. Disease in the brain 
and upper spinal cord improved overall with treatment, except for 
one focus in the pre-pontine cistern which grew in a plaque-like 
fashion.
2.1.3. Treatment at progression
In view of progressive weakness of the legs, she received an 
additional 30  Gy in 10 fractions to the spinal cord at T12–L4. 
Within a month of completing this treatment, she developed a 
flaccid paraplegia with loss of bladder and bowel control and a 
sensory level at T10. Her MRI confirmed progression (Figure 2). 
Thereafter, she was cared for by Hospice and died 5 months fol-
lowing her initial surgery.
2.2. a case with a Durable response  
to Treatment
2.2.1. Presentation
Our second patient was a 35-year-old man who presented with 
blurred vision that had been present for 3 months. His MRI at this 
time, showing a suprasellar mass, is shown in Figure 3.
He underwent craniotomy, via a pterional approach, for resec-
tion of the tumor. The pathology is shown in Figure 4. This shows 
how ATRT may be suspected on the basis of hematoxylin and 
eosin (H&E) staining alone. The diagnosis was confirmed by IHC 
for INI1.
A homozygous mutation in SMARCB1 was confirmed on Sanger 
sequencing. This was performed on the fresh-frozen, paraffin- 
embedded tissue. The sequencing covered the coding region and 
5′ and 3′ splice sites from nucleotide 37 to 47,120 in the reference 
sequence NT_011520.gbk (10). The mutation was des cribed as 
NM_003073.3: c.1148delC, NP_003064: p.P383fs*96. 
Occurring in exon 9, this causes a SMARCB1 protein frame-shift 
and the insertion of additional amino acids at the 3′ end of the 
protein. This mutation is predicted to lead to inactivation of this 
protein in the tumor.
2.2.2. Initial Treatment
MRIs performed following surgery demonstrated a nodule in the 
third ventricle that was believed to be persistent malignancy, as 
well as a nodule in the upper lumbar spinal cord, most likely a sign 
of leptomeningeal metastasis. Hence, cranio-spinal radiotherapy 
was given at a dose of 36  Gy in 20 fractions. Localized boosts 
were given to the primary site (20 Gy in 12 fractions) and the 
lumbar spine (8 Gy in 4 fractions). This treatment was completed 
3 months following his initial surgery.
He proceeded to receive chemotherapy using the St. Judes 
ATRT protocol. This was developed for children aged >3 and 
comprises 4 cycles of cisplatin with high-dose cyclophosphamide 
and vincristine, with autologous peripheral blood stem-cell 
transplantation (11). This took 5 months to complete.
Since completing treatment there has been no sign of residual/
recurrent disease at 2.5 years follow-up, clinically or on MRI, as 
seen in Figure 3.
Since his initial resection, he has suffered from panhypopitui-
tarism, a left homonymous hemianopia and short-term memory 
Figure 4 | Second patient. Immunohistochemistry. (a) Hematoxylin and eosin (H&E) stain, 200× magnification. The tumor comprises two main elements: sheets of 
large cells, many with a rhabdoid appearance (top) and small, more primitive-appearing cells (bottom). (B) (H&E) stain, 400×. This shows large cells, many with 
rhabdoid features and central mitoses. (c) INI1 stain, 400×. There is no nuclear staining in the tumor cells. A positive control is provided by the endothelial cells in 
the vessel at the center, and in other scattered glial and inflammatory cells.
4
Dardis et al. ATRT in Adults: Analysis
Frontiers in Neurology | www.frontiersin.org June 2017 | Volume 8 | Article 247
impairment. He also developed a peripheral neuropathy follow-
ing chemotherapy, most likely due to vincristine.
3. MeThODs
3.1. review of adult cases
A literature search was performed using PubMed and Google 
Scholar to search for all reported cases of ATRT in adults. All 
50 cases were tabulated; this is given as Supplementary Material 
(worksheet d1 in data sheet 1.xlsx). Many of these reports 
include similar tables; however, we noted a number of incon-
sistencies in these tables and ours is based on our reading of 
the original cases. While many prior authors have reported the 
‘classical’ features of ATRT via IHC (see below), we are the first to 
tabulate all pathological variables for each case.
3.1.1. Clinical Variables
In each case, we recorded age, gender, and location as well as 
presence of leptomeningeal metastases (LM) and details of 
treatment at initial diagnosis and time of first progression. As 
above, a meaningful response to treatment was rare if the dis-
ease progressed again after “second-line” approaches. ‘Third-line’ 
treat ments of any kind were exceptional and were not recorded.
The diagnosis of LM was based on clinical details and/or 
imaging features, e.g., in the case report of Wang et al. recurrence 
was spinal (distal from the original tumor) and appears to have 
originated from the leptomeninges on MRI, with subsequent 
intra-medullary spread (12).
A number of nominal (categorical) variables were ‘collapsed’ as 
this was such a small data set. Location, for example, initially had 
15 values; we also analyzed this as a 5- and 3-category variable in 
order to look for more general patterns. We also assessed whether 
the location was ‘central’ vs. clearly lateralized and whether the 
tumor was “next to CSF” based on imaging findings. Similarly, the 
extent of resection was considered as an ordinal variable (gross 
total > sub-total resection > biopsy) as well as binary (surgery or 
not). We analyzed age as binary (i.e., ≥40 years when diagnosed) 
as well as a continuous numeric variable.
3.1.2. Pathological Variables
We consider here only the pathology at the time of diagnosis 
of ATRT. We note that only 2/40 (5%) of patients in our series 
had an autopsy performed (where we could infer this informa-
tion). A summary table of all pathologic results is given as 
Supplementary Material (worksheet ihc1 in data sheet 
1.xlsx). Most of these variables relate to the presence of 
certain antigens via IHC.
For IHC, a variety of antibodies and names were used to 
assess the presence of various elements. We have standardized 
this by recording the antigen being tested. Keratin staining, in 
particular, used a range of antibodies and was variously reported 
by antibody, by weight of the stained keratin, by keratin type or 
at times as “keratin present.”
3.2. classification of ihc
3.2.1. Diagnosis of ATRT
Loss of INI1 protein expression (via IHC) is considered a defining 
feature of ATRT. Partial deletion of chromosome 22 (detected 
via FISH), where the gene (SMARCB1) is located, is considered 
as an equivalent test. Both of these tests began to be used widely 
after the year 2000. While both tests are considered to have 
a specificity of 100% for ATRT (in the appropriate setting), a 
negative result does not exclude the diagnosis. Such testing was 
reported in 23/50 (46%) of the cases we reviewed.
Prior to the advent of INI1 testing, the diagnosis was suspected 
on the basis of the appearance on standard H&E staining. Stain-
ing for the “classical” antigens vimentin, epithelial membrane 
antigen (EMA), and smooth muscle actin (SMA) was typically 
used as confirmatory. Both vimentin and SMA are classically 
associated with mesenchymal cells, although this does not imply 
a mesodermal origin for such cells. For example, constitutive 
expression of vimentin is recognized in arguably the most-
studied glial cell line, U-251 (13). Again, a negative test result for 
one of these antigens does not exclude the diagnosis.
3.2.2. IHC and Differential Diagnosis
While the diagnosis of ATRT is often quickly suspected in an 
infant, the initial differential diagnosis in adults is typically far 
wider. Thus, the range of IHC stains employed in adult cases is 
far greater and more variable. In total, 81 tests (using IHC) were 
performed in our case series. In 19 (23%) cases, the antigen of 
interest was tested for in just one specimen.
IHC often included tests for metastasases, germ cell tumors, 
neuro-endocrine tumors, and other primary tumors of the 
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nervous system (glial, medulloblastoma, neuroblastoma). Testing 
for a wider range of antigens (in adults vs. children) gives us a 
greater insight into the pathophysiology of ATRT.
Other possible differential diagnoses in adults may include 
primitive neuroectodermal tumor (PNET), choroid plexus car-
cinoma, rhabdoid meningioma, and germinoma. However, these 
entities generally have more characteristic immunohistochemical 
staining patterns with specific markers than the poly-phenotypic 
patterns seen in ATRT; also INI1 staining is retained.
3.2.3. Differential: Rhabdoid Glioblastoma
Tumors resembling ATRT, staining with glial fibrillary acidic 
protein (GFAP) as well as vimentin, SMA and EMA have been 
suggested to represent rhabdoid glioblastoma (GB) rather than 
ATRT (7). EMT in the setting of GB appears plausible as an entity 
distinct from ATRT. GB with EMT may have been misdiagnosed 
as adult ATRT (prior to the advent of testing for INI1), although 
this appears unlikely given the clinical and histological findings 
in our cases.
3.2.4. Germ Cell Layers
We used IHC to determine the putative germ cell layer of origin 
of each specimen. In so doing, we were guided by the tissues that 
are known to stain for an antigen under “normal” conditions. The 
website accompanying the textbook “Pathology Outlines” was 
particularly helpful in this regard (14).
Some stains are not restricted to one germ cell layer. An exam-
ple is keratin 8, which predominantly occurs in ectodermal tissue 
but is also recognized in endodermal tissue (15).
3.2.5. Classification
We thus classified pathological findings into the following groups:
 1. ‘ATRT specific’
•	 ‘Defining’ features (loss of INI1 or del(22))
•	 ‘Classical’ features (vimentin, EMA, SMA)
 2. Ectoderm
•	 Neural crest (neuronal, glial, neuro-endocrine, melanoma 
markers)
•	 Other ectodermal
 3. Endoderm
 4. Keratins
 5. Mesoderm
•	 Mesenchymal
•	 Leukemia/lymphoma markers
 6. Germ cell
 7. Others (found in a variety of tissues).
3.3. Quantitative analysis
Data analysis was performed using R (RRID:SCR_001905) 
(16–18). The complete analysis is available as Supplementary 
Material (data sheet 2.pdf). Nominal variables are given 
as fractions (percentage) and continuous variables as median 
(range).
We did not attempt to correct for multiple hypothesis testing, 
as the present work is exploratory (19). As the sample size is small, 
a priori we considered p values of <0.1 to be potentially worth 
reporting.
3.3.1. Associations
We began by looking at the significance of all two-variable asso-
ciations, using standard measures of strength and significance of 
association as follows:
Variable 1 Variable 2 Correlation p Value
Nominal Nominal Cramer’s V Chi-squared
Numeric Numeric Pearson’s r2 t-Test
Nominal Numeric Pearson’s r2 F-Test
3.3.2. Survival analysis
Time-to-event data were analyzed used the proportional-hazards 
model (PHM). We looked at the following outcomes:
 1. time to progression
 2. overall survival
 3. time from progression to death (to assess the effects of second-
line treatments).
Given the small number of observations and deaths, over-
fitting was a problem with multivariate PHMs.
Survival times are reported as a median with 95% confidence 
intervals (CI). Effect size is given as hazard ratio (HR, relative to 
control) and the p value is from the score test (or Wald test for 
multivariate models).
3.3.3. Missing Data
Given such a large quantity of missing data, we tried to compen-
sate in a number of ways:
•	 Recursive partitioning ‘looks ahead’ at survival to find the best 
split for the given data. It is particularly well suited to data sets 
where there is near-perfect prediction of outcome by certain 
variables. It also allows for a clear ordering of variables in 
terms of predictive importance (20).
•	 “Multivariate imputation by chained equations” uses repeated 
regression on the existing variables to estimate missing values. 
The technique does have a tendency to strengthen existing 
associations rather than developing new insights (21).
•	 The “nested cohort” design allows for more ‘accurate’ estimates 
from a PHM where a covariate is observed for only some 
subjects (the cohort). Sampling is stratified by a variable that is 
available on all cohort members.
This allows for frequency matching on confounders, or 
oversampling on the extremes of surrogate [markers] for 
exposures, to improve efficiency (22).
That is, this technique allows one to control for major confound-
ers in order to arrive at a more meaningful estimate of effect size 
and probability. In our case, we sought to better deter mine the 
effects of various treatments using a sampling scheme based on:
 1. the presence of LM or GFAP staining—as these were the 
major confounders of treatment
 2. the occurrence of death when the last recorded follow-up 
was performed—to try to control for censoring, i.e., the fact 
that certain patients were not followed up until death had 
occurred.
TaBle 1 | Immunohistochemistry (IHC) of adult ATRT.
stain long name +ve n %
‘Defining’ features of aTrT
del(22)(q) 22q11.2 distal deletion 13 15 87
INI1 Integrase interactor 1/SMARCB1/hSNF5 1 23 4
‘classical’ aTrT markers
vim Vimentin 33 33 100
EMA Epithelial membrane antigen 29 35 83
SMA Smooth muscle actin 18 32 56
neuronal
S100 100% soluble in (NH4)2-SO4 13 27 48
nfp Neurofilament protein 10 15 67
nse Neuron-specific enolase 2 6 33
Nestin 2 2 100
glial
GFAP Glial fibrillary acidic protein 12 30 40
neuro-endocrine
Synaptophysin Major synaptic vesicle protein p38 6 22 27
Keratin
ker Keratin (any, including type not specified) 20 49 41
ck8 Keratin 8; 52 Da 12 16 75
Mesenchymal
Desmin 0 19 0
Myoglobin 0 4 0
Others
CD34 Hematopoietic progenitor cell  
antigen CD34
3 11 27
CD99 Single-chain type-1 glycoprotein 2 7 29
p53 Cellular tumor antigen p53 4 5 80
+ve, positive result, i.e., staining for antigen present; n, number of cases tested; %, 
percentage positive/number tested.
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4. resulTs
4.1. Demographics
The 50 patients reviewed (including the present cases) had a 
median age of 32 (18–65); 27 (54%) were females. Of those of 
childbearing age, 3/20 (15%) were pregnant when the diagnosis 
was made.
4.2. ihc
Some of the more significant findings on IHC are given in Table 1. 
As above, the complete table, with explanations, is given in (data 
sheet 1.xlsx).
Defining features of ATRT were found in almost all cases 
where these were assessed: loss of INI1 in 23/24 (96%), del22q 
in 13/15 (87%). It is tempting to consider those cases where 
these were absent as “false negatives”; we will return to this in 
the discussion.
Of the “classical” features, only vimentin was universally posi-
tive (33/33) in our series. Germ cell markers, where assessed, were 
uniformly negative. Keratins were variably expressed; keratin 8 
was found in the highest proportion of samples assessed, 12/16 
(75%). As above, we cannot use this help attribute a germ cell 
layer of origin to a specimen (15).
4.2.1. Nestin
Markers of neuronal, glial, and neuro-endocrine differentiation 
were relatively common (c. 25–75%). Of particular interest is 
the presence of nestin in 2/2 cases studied. This is considered a 
marker of ‘neuroepithelial stem cells,’ is active in embryogenesis, 
and is downregulated in maturity, when expression of neurofila-
ment protein and GFAP occur.
Interestingly, nestin is also expressed in developing muscle 
(presomitic mesoderm), to be replaced by desmin in maturity. 
Yet, desmin was universally absent in our sample (0/19). Other 
markers of mature muscle differentiation were also lacking, as 
well as the myogenic regulatory factor MYOD1 (0/2 cases), which 
is involved in myogenesis.
4.2.2. CD34
The hematopoietic system is thought to be derived from meso-
derm; as such the presence of markers more typically used in the 
diagnosis of leukemia and lymphoma in our sample may at first 
appear anomalous. However, CD34 is recognized to occur in 
tumors of neuroepithelial origin, particularly those of childhood 
(23). It is also expressed on endothelial cells.
4.2.3. CD99
CD99 has been less well studied in CNS tumors. It is recognized to 
occur in “primary neuroepithelial tumors of the kidney,” an entity we 
believe to be closely related to ATRT (24). It is also present in epend-
ymoma, peripheral primitive neuroectodermal tumor, and in the rare 
chordoid glioma, all of which are of neuroepithelial origin (25–27).
4.3. associations
A number of striking associations are given in Table 2. Additional 
relationships of significance statistically but of debatable impor-
tance biologically are given as in the Supplementary Material as 
data sheet 2.pdf.
4.3.1. Demographics and Location
Where the tumor was in or next to the pituitary, 10/11 cases were 
in females (91%). The predilection of adult ATRT for this loca-
tion has been recognized, although the sex-specificity seen here 
is novel (28).
Tumors of the spinal cord were associated with increasing age 
(Pearson’s r = 0.43, F test p = 0.002).
4.3.2. IHC
Tumors with LM when diagnosed were much more likely to show 
GFAP staining (n = 30, chi-squared p = 0.02), implying that glial 
differentiation is a major risk factor for this complication.
All tumors that showed synaptophysin staining also stained 
for SMA (n = 20, chi-squared, p = 0.03). Synaptophysin was the 
only neuroendocrine marker commonly assessed in the sample; 
this finding suggests that differentiation along such lines is 
associated with a greater tendency to manifest a mesenchymal 
phenotype.
Findings regarding neural differentiation were difficult to 
interpret. Neurofilament protein (NFP) staining was present in all 
female patients (6/6) vs. 4/9 males (chi-square p < 0.1). Strangely, 
staining for NFP and neurospecific enolase (NSE) appeared mutu-
ally exclusive, i.e., where one was positive the other was negative, 
although there were only 4 subjects where both were checked. No 
cases where NFP staining was absent stained for GFAP (n = 15).
TaBle 2 | Significant (p < 0.1) two-variable associations.
chi-square p
assOciaTiOns WiTh lOcaTiOn
gender 4th Ventricle lateral 
Ventricle
Pineal Pituitary spinal 
cord
Male 4 13 2 0 3 0.046
Female 3 7 4 10 3
surgery, radiation, and chemotherapy
No 3 14 0 6 4 0.007
Yes 3 3 5 4 0
gender lateral Mid-line
Male 15 7 0.043
Female 9 17
age Brainstem lateral 
ventricle
spinal 
cord
18–40 12 22 1 0.004
>40 6 4 5
leptomeningeal metastases at recurrence
No 2 16 2 0.039
Yes 6 5 1
OTher assOciaTiOns
leptomeningeal 
metastases
gFaP no Yes
−ve 16 2 0.018
+ve 5 7
synaptophysin
sMa −ve +ve
−ve 9 0 0.031
+ve 5 6
neurofilament protein
gender −ve +ve
Male 5 4 0.094
Female 0 6
GFAP, glial fibrillary acidic protein; SMA, smooth muscle actin.
TaBle 3 | Percentages of patients without progression, and surviving, at 
timepoints following diagnosis.
Time from diagnosis Progression-free (%) surviving (%)
6 months 46 76
12 months 33 64
2 years 20 39
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4.4. Treatment
4.4.1. Surgery
Surgery (SX) at diagnosis was a cornerstone of treatment; in only 
one case was this not undertaken, where imaging initially sug-
gested vestibular schwannoma and radiotherapy was used instead 
(12). Gross total resection (GTR) was reported in 10/43 (23%) of 
cases. This was most common for those tumors located next to a 
lateral ventricle. Subtotal resection was most common for tumors 
of the pituitary and pineal gland.
4.4.2. Adjuvant Treatment
Radiotherapy (RT) was undertaken in 33/42 (79%) and systemic 
chemotherapy (CT) in 17/42 (40%). Cranio-spinal irradiation 
(CSI) was performed in 5/34 (15%). All three approaches (SX, 
RT, and CT) were used in 15/42 cases (36%). This multimodality 
approach was most commonly used for those tumors next to a 
lateral ventricle (Table 2).
Intrathecal CT was used in just two cases other than our first 
patient. In contrast to our use of liposomal cytarabine, these two 
patients were treated with small quantities of methotrexate: three 
and one dose(s), respectively (29, 30).
4.4.3. Treatment at recurrence
When disease re-occurred/progressed, lower proportions of 
patients received treatment. Additional SX was attempted in 
12/26 (46%), RT in 13/26 (50%) and CT in 11/26 (42%).
4.5. survival
The median time to progression (TTP) was 5 months (95% CI 
3–18). Overall survival (OS) was 23 months (14–56). Time from 
progression until last observation or death (time from progres-
sion to death, TPD), in the 27 patients where this was applicable 
and available, was 8  months (5–28). The fractions of patients 
without progression, and surviving, at various points in time 
from diagnosis are shown in Table 3.
4.5.1. Long-term Survivors
Apart from our second patient, two others are reported to have 
survived for more than 3 years (31, 32). Unlike our patient, both 
re-occurred on multiple occasions following their initial treat-
ment. The first was a frontal lesion that required complete exci-
sion 6 times (and once in the contralateral frontal lobe) as well as 
receiving radiotherapy, Gamma Knife radiosurgery and systemic 
chemotherapy; after 7  years of relapsing disease, she remained 
disease free for another 10 years. The other was a parietal lesion 
which re-occurred 3 times over the course of 9 years and which 
appeared stable 1 year after most recent treatment. Interestingly, 
this patients’ tumor was diagnosed and treated as glioma, at 
presentation and at first re-occurrence. The diagnosis of ATRT 
was subsequently made in retrospect due to the absence of INI1 
by IHC in all specimens.
4.5.2. Clinical Variables and IHC
Significant predictors of survival in PHMs are shown in Table 4. 
Of note, LM and GFAP staining appear as significant predic-
tors in almost all of these models. While LM and GFAP are 
correlated, LM appears to be the more important predictor, 
particularly in multivariable PHMs. The effect of LM on OS is 
shown in Figure 5.
4.5.3. Treatments
“Over-fitting” was a problem when using surgery as an ordinal-
scale variable in multivariate models. Instead, we give this as 
“gross total resection?” (GTR, yes/no). Regarding OS, only SX 
and multimodality treatment (SX, RT, and CT, HR = 0.3) were 
significant predictors. Both GTR and CT were significant predic-
tors in the multivariable PMH for OS.
TaBle 4 | Leptomeningeal metastases and GFAP staining are significant 
predictors in most proportional-hazards models.
Variable n hr p
uni-variable score
TTP RT 33 0.13 <0.01
SX 33 Ordinal 0.02
GFAP 22 1.9 0.19
LM 33 2.4 0.04
GTR 33 0.86 0.75
OS LM 41 4.6 <0.01
GFAP 27 3.1 0.04
SX 40 Ordinal <0.01
SRC 40 0.25 0.02
Pregnant 18 4.5 0.05
GTR 39 0.55 0.3
TPL LM 27 6.7 <0.01
GFAP 18 7.5 <0.01
Multivariable Wald
TTP LM 4.4 0.01
n = 21, e = 14 RT 21 0.32 0.13
GTR 0.41 0.20
GFAP 2.3 0.18
OS LM 27 5.5 0.02
n = 27, e = 15 GFAP 2.4 0.25
GTR 0.27 0.07
CT 0.24 0.03
RT 1.5 0.6
TPL LM 18 3.7 0.4
n = 18, e = 14 GFAP 2.4 0.6
p values: for uni-variable models = score test; for multivariate models = Wald test.
HR, hazard ratio; TTP, time to progression; OS, overall survival; TPL, time from 
progression to last follow-up/death; n, number of observations; e, number of events 
(progression or death); RT, radiotherapy; SX, surgery (ordinal; HRs not shown); 
GFAP, glial fibrillary acidic protein; LM, leptomeningeal metastases; GTR, gross total 
resection (vs. other value for surgery); SRC, surgery, radiation, and chemotherapy; CT, 
chemotherapy.
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The effects of the most common initial treatments on OS, 
when controlling for LM and GFAP (and death, in both cases), 
are shown in Table 5.
5. DiscussiOn
5.1. Pathogenesis
5.1.1. Location at Diagnosis and Implications  
for Anatomical Origin
ATRT in adults has a predilection for mid-line structures, particu-
larly the pineal and pituitary glands. These are circumventricular 
organs, which are now recognized as a source of neural stem cells 
in adults (33).
ATRT may be said to be the prototypical tumor of infancy, in 
having the earliest onset and highest perinatal incidence of such 
tumors. Tumors of infancy in general are thought to arise from 
cells that have not completed the process of terminal differentia-
tion and continue to undergo hyperplasia from the latter half of 
pregnancy to age 3 or so (34).
Our case series suggests that there remains a pool of slowly 
dividing ‘ectodermal stem cells’ in at least some of these circum-
ventricular organs that remains capable of acquiring carcinogenic 
mutations throughout most of adulthood (35). The proximity of 
these organs to CSF may explain the close association of these 
tumors with such locations and their tendency to develop LM. Of 
note, when ATRT occurs in a cerebral lobe, it typically appears in 
communication with a lateral ventricle.
We suspect that in many cases the tumor has already spread 
via CSF prior to diagnosis. This would help to explain the pro-
posal of such entities as “primary diffuse cerebral leptomeningeal 
ATRT” and “ATRT arising from the acoustic nerve”; these struc-
tures appear unlikely to be points of origin for ATRT (12, 36).
The strong association between pituitary involvement and 
female gender is consistent with the greater mitotic activity 
of the pituitary in females throughout the lifespan (37). We 
acknowledge there remains much work to be done in this area.
5.1.2. IHC and Implications for Cell Type of Origin
As summarized in Table  1, findings on IHC suggest a tumor 
of ectoderm origin with EMT. For example, the combination 
of EMA (epithelial, 83%), vimentin (mesenchymal, 100%), and 
complete absence of markers of mature mesenchyme (desmin, 
myoglobin, 0%) are characteristic of such a phenotype.
In this regard, the name “ATRT” is somewhat misleading 
in that it is clearly not a teratoma and does not contain ele-
ments originating from mesoderm or showing skeletal muscle 
differentiation.
Classification of IHC by cell type and germ layer in adult 
ATRT has also been undertaken by Raisanen et  al. (38). Their 
table is similar to our own, albeit with a smaller sample size. The 
authors do not attempt to infer any implications for pathogenesis 
from their table.
5.1.3. Germline Mutations and del22q
Loss of INI1 is not sufficient to cause ATRT. This is shown by 
the lack of complete penetrance of ATRT in germline mutations 
In assessing the effects of treatment, we acknowledge that 
we are not “comparing like with like,” i.e., patients for whom a 
certain treatment is not possible will be expected to have a worse 
outcome. Regarding surgery, GTR is generally the goal, where 
possible; those for whom this is not feasible will tend to have a 
worse prognosis, no matter the approach to surgery. Similarly, 
those for whom CT is impossible will tend to have poorer survival 
outcomes. However, significant comorbidities or disabilities due 
to disease (thus limiting the use of CT) were exceptional at the 
time when CT was commenced.
4.6. recursive Partitioning
The most important predictor of OS was clearly LM; this is shown 
in Figure 6. When LM was excluded from the analysis, multi-
modality therapy (SX, RT, and CT) became the most significant 
variable (Supplementary Material, data sheet 2.pdf).
4.7. Multiple imputation and  
“nested” PhM
Applying these techniques to the potentially important predic-
tors already identified tended to confirm the results above (data 
sheet 2.pdf).
TaBle 5 | Chemotherapy is the most important predictor of overall survival, 
when controlling for leptomeningeal metastases and GFAP staining (using 
‘nested cohort’ proportional hazards models).
Variable hr p
LM CT 0.45 0.09
n = 39, e = 24 RT 0.56 0.3
GTR 0.43 0.3
GFAP CT 0.31 <0.01
n = 27, e = 15 RT 0.64 0.5
GTR 0.31 0.1
HR, hazard ratio; GFAP, glial fibrillary acidic protein; LM, leptomeningeal metastases; 
n, number of observations; e, number of events (deaths); CT, chemotherapy; RT, 
radiotherapy; GTR, gross total resection (vs. other value for surgery).
Figure 6 | Recursive partitioning analysis shows LM to be the most 
important predictor of overall survival. Abbreviations: LM, leptomeningeal 
metastases; SRC, surgery, radiation and chemotherapy (≥0.5 means all 
modalities employed); Sx, Surgery; gtr, gross total resection; sx, surgery 
(extent unspecified); str, subtotal resection; bx, biopsy; none, no surgery.  
Key: circles, branching nodes; squares, terminal nodes; green, better 
outcomes; pink, worse outcomes; upper, no. predicted event rate; 
lower, no. no. events/no. at risk.
Figure 5 | Overall survival is significantly worse in patients with leptomeningeal metastases (LM) at the time of diagnosis. Time scale is shown in months.  
Hazard ratio 4.4, score test p = 0.0005.
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22q. The only case we reviewed where this seemed likely was 
our case with a prolonged response to treatment. The patent had 
macrocephaly and a history of spinal schwannoma as a teenager. 
None of the other reported a personal or family history of 
dysmorphism or of tumors seen in the rhabdoid-predisposition 
syndrome.
Nonetheless, it has been recognized that germline mutations 
in SMARCB1 germline mutations are not always inherited and 
unaffected adult carriers are recognized (40). In this series of 
100 patients, those with germline mutations tended to pre-
sent at a much younger age, at a median of 5  months (range 
birth—5  years) vs. 18  months (birth—17  years) for those with 
acquired mutations. However, in 4 of 7 cases of inherited muta-
tions, the parents appeared completely unaffected. The authors 
also recognize germline/gonadal mosaicism in their sample, 
i.e., the mutation must have been present within parental gametes 
but not somatic cells.
(distal 22q11 microdeletion syndromes) (39). None of the cases 
of ATRT in this series, including our own, had germline analysis 
performed to look for a mutations or deletion of chromosome 
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Such germline mutations result in a phenotype known as 
“rhabdoid predisposition syndrome.” In addition to ATRT, car-
riers appear predisposed to rhabdoid tumors (renal and extra-
renal), PNET, medulloblastoma, choroid plexus carcinoma and 
schwannoma (41). These authors also suggest the mutation as a 
cause for cases of Li–Fraumeni-like syndrome (patients with a 
childhood cancer or “sarcoma” aged <45 and a family history of 
cancer at a young age, in those lacking germline TP53 mutations).
Thus, we recommend somatic analysis in addition to analysis 
of the tumor, even in adult patients (42). Analysis of parental 
somatic and germline DNA also appears desirable.
5.1.4. INI1, del22q, and Epigenetic Subgroups
The only consistent genetic change in these tumors appears to 
be loss of INI1 due to SMARCB1 mutations (which are variable) 
(4, 43). Mutation of SMARCA4 is recognized as an alternative 
inciting event in rare cases, perhaps accounting for the single 
patient in our series with preserved INI1 expression. The lack 
of other consistent candidate oncogenic mutations has led to the 
recognition that epigenetic changes are crucial to pathogenesis. 
Three such epigenetic subgroups are now recognized (44). There 
were no adults in this recent work characterizing subgroups (age 
range: birth to 9.5 years). The subgroups are named based on the 
pathways most commonly upregulated, here shown with some of 
the genes whose expression is characteristically increased:
ATRT-TYR Melanogenesis pathway EZH2, DNA methyltransferases 
(DNMTs), CCND1, VEGFA, ERBB2
ATRT-SHH Hedgehog pathway EZH2, DNMTs, CDK6
ATRT-MYC MYC pathway MYC, HOX genes, EZH2, DNMTs, 
ERBB2
Phenotypically, the ATRT-TYR subgroup is strongly associ-
ated with a supratentional location vs. ATRT-MYC; ATRT-SHH 
appears in both locations.
Further characterization of phenotype by subgroup may 
be facilitated by preserving the methylation status of DNA in 
the tumor specimen. We suggest that fresh-frozen material be 
obtained for this purpose where practical. Technical advances 
continue to make methylation profiling more practical in forma-
lin fixed, paraffin-embedded samples.
5.1.5. Chromatin Remodeling and EMT
EMT is known to result in a more ‘open’ chromatic structure (9). 
This is necessary to facilitate de-differentiation, i.e., the transcrip-
tion of mRNA, which is typically unavailable to the differentiated 
epithelial cell. This includes a shift in energy (ATP) production 
from oxidative phosphorylation to glycolysis. This is necessary 
for the supply of energy of biosynthetic precursors, of a balanced 
redox status and appears necessary to maintain the undifferenti-
ated state.
Chromatin remodeling complexes such as INI1 have been 
implicated in various cancers (45). INI1 is now recognized as a 
tumor suppressor, due to its mutation in tumors including choroid 
plexus carcinoma, medulloblastoma, primitive neuroectodermal 
tumor, and chronic myeloid leukemia. INI1 is a member of the 
SWI2/SNF2 remodeling complex, which is ATP dependent.
Loss of function of these chromatin remodeling complexes 
enables the development of the ‘open’ structure required for EMT. 
It remains unclear why loss of INI1 leads to diverging epigenetic 
phenotypes.
5.2. clinical Trials
Ongoing and recently completed trials for this condition are 
tabulated in the recent review by Fruhwald et al. (3). The dearth 
of clinical trials enrolling adults >21 years old, just seven at the 
time of writing, is shown in Table 6.
As a rare condition, even in children, there is some justifica-
tion for ‘lumping’ ATRT with similar tumors. This is particularly 
rational when the intervention is relatively non-specific, e.g., 
radi otherapy, traditional ‘cytotoxic’ chemotherapy (and soon, 
perhaps, immunotherapy).
In the case of more ‘targeted’ treatments, the pool of analo-
gous diseases will be much smaller. Two of the seven trials may 
be said to be target aspects of the biology of ATRT. It is striking 
that the trial of alisertib aims to inhibit aurora kinase A, an 
enzyme that has been implicated in EMT. This trial includes 
malignant rhabdoid tumors (MRT), which show EMT but do 
not lose INI1 protein (46). MRTs, as well as rhabdoid tumors 
of the kidney (also showing EMT), are included in the trial of 
tamezostat (an EZH2 inhibitor). While beyond the scope of the 
current work, we suggest that the term “rhabdoid” is synony-
mous with EMT. Interestingly, the trial of tamezostat considers 
other tumors lacking INI1 to be sufficiently similar to be worth 
including.
The other five trials that include ATRT are relatively ‘non-
specific’ and compensate for its low incidence by combining 
it with other ‘serious’ tumors, typically also of childhood. For 
example, four of five include PNET and medulloblastoma.
5.3. Treatment
As ATRT is primarily a disease of infancy, co-ordination of 
treatment between pediatric and adult oncology services appears 
appropriate.
5.3.1. Chemotherapy
ATRT usually occurs before CSI can be given safely, i.e., in those 
aged <3. Thus, CT has traditionally been a cornerstone of treat-
ment. We suggest that a primary guiding factor be penetration 
into CSF (given the high prevalence of LM) as well as into the 
intraparenchymal tumor. As these tumors tend to disrupt the 
blood–brain barrier (BBB) and are often next to parts of the brain 
with no BBB, penetration of CT into normal brain parenchyma 
does not appear to be of prime concern.
In the rare cases when ATRT is localized and can be completely 
excised, local RT appears appropriate; arguably, a protocol similar 
to that used for glioblastoma can be adopted in such cases.
The most common approach to CT typically involves cyto toxic 
and relatively non-specific agents. Ifosfamide, carboplatin, and 
etoposide (ICE) was the most common regimen in our series, a 
protocol typically used for sarcoma and lymphoma. These agents 
have reasonable brain and CSF penetration (47–49). However, 
given the grave prognosis of this condition, a more aggressive 
approach appears warranted in adults, as in our second case.
TaBle 6 | Ongoing clinical trials enrolling patients aged >21.
ncT iD agent MOa ca Mc age Phase n cohorts
http://clinicaltrials.gov/
show/NCT02601950
Tazemetostat EZH2 I No Yes >16 2 150 rhabdoid: ATRT
MRT
RTK
Refractory synovial sarcoma
+ SS18-SSX rearrangement
INI1 −ve: EMPNST
EMC
Myoepithelial Ca
Chordoma
RMC
Epithelial sarcoma
http://clinicaltrials.gov/
show/NCT01505569
1–3 cycles:
Ifosfamide
Etoposide
→Carboplatin
→Thiotepa
Autologous
peripheral
blood
stem cell
transplant 
Yes No <70 SOC 20 r/r solid tumor
CNS tumor: ATRT
PNET age <3
High risk MB age <3
MB age <8 months
Anaplastic MB
Germ cell tumor
http://clinicaltrials.gov/
show/NCT00445965
131I-3F8 Ab Ganglioside
GD2
No No Any 2 131 CNS/LM tumor
GD2 +ve
http://clinicaltrials.gov/
show/NCT00983398
Intra-arterial: Yes No 1–30 1/2 55 r/r CNS
embryonal
tumor:
ATRT
PNET
MB
Medulloepithelioma
Pineoblastoma
Ependymoblastoma 
Melphalan Alkylating
Carboplatin DNA repair
Mannitol Osmotic
Thiosulfate Adsorbent
Germ cell tumor
http://clinicaltrials.gov/
show/NCT02114229
Alisertib Aurora A I No Yes <22 2 180 ATRT (with chemoTx)
r/r: ATRT
MRT
http://clinicaltrials.gov/
show/NCT02684071
Intraventricular methotrexate 
with systemic:
Topotecan
Cyclophosphamide
Yes No <22 2 10 r/r: ATRT
PNET
Topoisomerase I MB
Alkylating Ependymoma
http://clinicaltrials.gov/
show/NCT02458339
Methotrexate via 4th ventricle Anti-folate Yes No 1–21 1/2 18 r/r: ATRT
PNET
MB
Ependymoma
CPCa
NCT ID, National clinical trials identifier; CA, commercially available; MOA, mode of action; MC, multi-center (i.e., ≥3 sites); n, number of patients (estimated accrual); Ab, antibody; 
I, inhibitor; EZH2, enhancer of zeste homolog 2 (enzyme); SOC, standard of care/protocol; r/r, recurrent/refractory (progressive); MRT, malignant rhabdoid tumor; RTK, rhabdoid 
tumor of the kidney; EMPNST, epithelioid malignant peripheral nerve sheath tumor; EMC, extra-skeletal myxoid chondrosarcoma; RMC, renal medullary carcinoma; PNET, primitive 
neuroectodermal tumor; MB, medulloblastoma; CPCa, choroid plexus carcinoma.
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5.3.2. Radiotherapy
Several reports demonstrated the beneficial role of adjuvant 
RT after surgical resection in patients with ATRT (11, 50, 51). 
However, RT is a significant challenge in those younger than 
3 years old (52).
The benefit of combining RT with SX in ATRT has been shown 
by Lau et al. (53). In a sample of 171 pediatric and 3 adult cases, 
they report an increase in median survival from 1.9 ±  0.4 to 
5.9 ± 0.7 years in those who had RT in addition to SX. Buscariollo 
et al. confirmed the value of RT in another retrospective series, 
this with 144 patients, where median survival improved from 6 
to 34 months (p < 0.001) (54).
Once a decision on the use of RT has been made for a patient 
with ATRT, factors such as timing, dosing, and technique need 
to be considered.
Chen et al. reported improved disease-free survival in patients 
who had a total dose more than 50 Gy (55). Significant improve-
ment in median survival was reported in patients who had a 
shorter interval between SX and RT. RT delivered early vs. latein 
the course of treatment has also been associated with improved 
survival (11).
Proton therapy may be especially attractive in younger pati ents, 
in order to minimize the risk of late complications. Encouraging 
results with local conformal proton therapy have been reported 
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by Bernstein et  al. (56). Nine of ten patients with ATRT (with 
a median age of 1.8  years) had no evidence of disease, with a 
median follow-up of 27.3 months.
As distal relapse is associated with higher mortality and as the 
majority of distant relapses occur within the CNS, CSI is recom-
mended is those older than 3 years old: 23.4 Gy to the neuraxis 
(with 54 Gy to the tumor bed) is recommended inpatients older 
than 3 years old. Younger patients have been treated using either 
no adjuvant RT or local-only RT, with a trend toward improved 
survival with the addition of RT.
5.3.3. A Combined Approach
Promising results have been already been shown in children >3 
with PNET undergoing CSI followed by high-dose CT and in 
the setting of recurrent CNS tumors (57, 58). Stem-cell rescue 
was required with these more aggressive regiments, either from 
peripheral blood or bone marrow. Given its known role as a 
radiosensitizer and excellent brain and CSF penetration, the use 
of temozolomide during radiotherapy also appears reasonable 
(59). Early use of intrathecal chemotherapy also appears rational. 
As it is well tolerated in long-term use, it may also be an accept-
able approach in those patients who would not tolerate more 
aggressive forms of CT.
6. cOnclusiOn
ATRT in adults carries a grave prognosis, particularly in those 
cases with leptomeningeal spread. We postulate that ATRT is a 
tumor of neuroectodermal origin that demonstrates mesenchy-
mal transition.
Our cases indicate the possibility of improved outcome with 
more aggressive therapy. CSI should always be considered in 
adults. The use of stem-cell rescue allows for the use of more 
aggressive chemotherapeutic regimens than has hitherto been 
the case.
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